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Sub-regions of hypoxia exist within all tumors and the presence of intratumoral hypoxia has an adverse impact on
patient prognosis. Tumor hypoxia can increase metastatic capacity and lead to resistance to chemotherapy and
radiotherapy. Hypoxia also leads to altered transcription and translation of a number of DNA damage response and
repair genes. This can lead to inhibition of recombination-mediated repair of DNA double-strand breaks. Hypoxia
can also increase the rate of mutation. Therefore, tumor cell adaptation to the hypoxic microenvironment can drive
genetic instability and malignant progression. In this review, we focus on hypoxia-mediated genetic instability in
the context of aberrant DNA damage signaling and DNA repair. Additionally, we discuss potential therapeutic
approaches to specifically target repair-deficient hypoxic tumor cells.
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The tumor microenvironment is characterized by sub-
regions of nutrient deprivation, low extracellular pH,
high interstitial fluid pressure, and hypoxia. Hypoxic
areas arise when oxygen consumption exceeds that of
supply [1]. In normal tissues, the oxygen supply matches
the metabolic requirements of the cells. However, in lo-
cally advanced solid tumors, the oxygen consumption
increases significantly, resulting in inadequate oxygen
supply to some regions of the tumor. In addition, the
blood vessels within a tumor microenvironment are usu-
ally chaotic, dilated and irregularly organized [1]. In nor-
mal tissues, the oxygen tension (pO2) ranges from 10 to
80 mmHg (or 1.25% to 10% O2). However, tumors often
contain regions where the oxygen concentration can sig-
nificantly decrease to less than 5 mmHg (or < 0.6% O2)
[2,3]. Clinical studies using pO2 electrodes, hypoxia im-
aging (positron emission tomography (PET)), and immu-
nohistochemistry (IHC) have demonstrated that hypoxia
is a characteristic of all solid tumors [4]. Hypoxic regions* Correspondence: rob.bristow@rmp.uhn.on.ca
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stated.within tumors can be measured by IHC assessment of
intrinsic and extrinsic hypoxic cell biomarkers. Intrinsic
biomarkers of hypoxic response include hypoxia indu-
cible factor 1 (HIF1α), vascular endothelial growth factor
(VEGF), carbonic anhydrase IX (CAIX), osteopontin and
glucose transporters 1 and 3 (GLUT1, GLUT3) and the
extrinsic biomarkers include drugs that specifically accu-
mulate or become bio-reduced to form adducts within
hypoxic cells such as pimonidazole (PIMO), EF5 and
CCI-103 F [5]. Increased levels of hypoxia correlates
with genetic instability, tumor progression, local and sys-
temic resistance; all leading to poor clinical outcome fol-
lowing treatment [6-12].
Tumor cells that lie beyond the diffusion distance for
oxygen (> 70 μm away from blood vessels) can quickly
outstrip blood supply and are exposed to chronically low
oxygen tensions [13]. These diffusion-limited conditions
for duration of days are referred to as “prolonged” or
“chronic hypoxia” [14]. The cells in these regions are be-
lieved to remain hypoxic until they die (due to lack of
oxygen or nutrients) or are reoxygenated [15]. Hypoxia
can also be transient or “cycling” due to acute perfusion
changes in the tumor vasculature. The blood vessels
formed during unregulated angiogenesis contain severe
structural and functional abnormalities and can tempor-
arily close and re-open, leading to cycles of acute hyp-
oxia/anoxia (from minutes to hours) followed bytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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and chronic hypoxia co-exist within a tumor resulting in
significant gradients of oxygen consumption leading to
intratumor heterogeneity [16].
In an experimental setting, cellular hypoxia can be
induced by placing cultured tumor cells in complete
media in environmentally-controlled chambers in which
oxygen levels in the gas phase are maintained at 0.01-3%
[17]. These hypoxic conditions may not be lethal nor
growth inhibitory to selected tumor cell lines when cul-
tured in the presence of excess glucose and nutrients.
However, when cells are placed in the complete absence
of oxygen (anoxia), most cells will stop proliferating due
to the activation of anoxia-mediated intra-S phase arrest
mediated by the ataxia telangiectasia mutated (ATM)
and ataxia telangiectasia and RAD3-related (ATR)
kinases [18-21]. If prolonged, this arrest of DNA replica-
tion becomes irreversible leading to cell death mecha-
nisms [22]. Hence, a permanent anoxic microenvironment
(e.g. close to 0% O2) eventually leads to cell death whereas
tumor cells that exist in hypoxic microenvironments (e.g.
0.2 to 1% O2) could adapt and continue to proliferate with
altered biology [12,14]. Tumor cells that adapt to low oxy-
gen conditions gain an overall advantage for growth and
leads to treatment resistance following chemotherapy or
radiotherapy [14]. Therefore, the study of proliferating
hypoxic cells is important as it represents a clinically-
challenging, sub-population of resistant cells with the po-
tential of clonal expansion and metastatic spread.
Clinical observations, supported by pre-clinical data,
have demonstrated that hypoxia is associated with an in-
creased capacity for metastasis [23]. Metastasis is a
multi-step process that involves disruption of cell adhe-
sion to the neighboring cells and to the basement mem-
brane, migration through the extracellular matrix,
penetration of vessel walls and circulation exit, and fi-
nally initiation of angiogenesis to allow tumor growth in
the target tissue [24]. Hypoxia can lead to altered ex-
pression of many proteins involved in this process by
regulating the expression of E-cadherin (cell-cell con-
tact), urokinase-type plasminogen activator receptor
(uPAR; degradation of extracellular matrix proteins),
hepatocycte growth factor (HGF; cellular motility) and
vascular endothelial growth factor (VEGF; angiogenesis
and vascular permeability) [14,24,25]. Hypoxia also
limits the effectiveness of many anti-cancer therapies.
The efficiency of ionizing radiation to create lethal DNA
breaks is strongly associated with oxygen tension and
creation of free radicals. Oxygen can react with the dam-
aged DNA bases created by free radicals to yield a more
stable adduct and this reaction chemically “fixes” the
damage [2]. Indeed, oxygenated cells can be two to three
times more sensitive to radiation than hypoxic or anoxic
cells [12,26]. However, ionizing radiation under anoxicconditions has been shown to increase the levels of
DNA-protein crosslinks [27,28]. Moreover, poor drug
distribution and decreased proliferation can decrease the
efficacy of many chemotherapy drugs [12,14]. Thus, the
cells in hypoxic regions can adapt to become resistant to
radiotherapy and chemotherapy and ongoing selection
of increasing aggressiveness [29]. Therefore, two main
clinical entities are associated with hypoxic tumors: in-
creased local tumor cell resistance and development of
systemic metastasis. Despite these data, hypoxia-targeted
therapy is still not a standard of current cancer treat-
ments [30]. Therefore, the study of hypoxic cells is im-
portant in order to gain a further understanding of the
consequences of the hypoxic microenvironment for the
development of genetic instability as a precursor to
tumor progression and therapy-associated resistance.
Hypoxia-mediated genetic instability
Tumor cells can acquire multiple adaptations in the se-
lective pressure of the tumor microenvironment. Hyp-
oxia inducible factor 1α (HIF1α) is a transcription factor,
which is kept at low levels in the presence of oxygen by
von Hippel-Lindau protein (VHL)-mediated degradation
[31]. In hypoxic conditions, HIF1α is quickly stabilized
and regulates a number of genes including those in-
volved in vascularization, glycolysis and pH homeostasis
[31]. HIF1α is crucial for hypoxic adaptation, and over-
expression of HIF1α is associated with a poor disease
outcome [32]. Loss of HIF1α control can promote the
malignant phenotype and genomic instability via interplay
with oncoproteins such as c-MYC [33-37]. Oncogene
amplification, DNA replication stress, and deregulated
DNA damage checkpoint signaling in hypoxic tumor
cells, together with the ability to escape cell death, can
allow cells to proliferate in the presence of damaged
DNA and acquire further mutations [38,39]. The vicious
cycle is accelerated by increased frequency of mutations
and by the ability of hypoxic cells to downregulate DNA
repair; therefore further driving genomic instability (see
Figure 1) [14,40]. Moreover, when hypoxic cells become
reoxygenated, they may acquire further DNA damage as a
result of a sudden burst of free radicals [41,42]. We now
discuss further hypoxia-mediated genomic instability in
the context of the DNA damage signaling and inhibited
DNA repair.
Hypoxia and the DNA Damage Response (DDR):
checkpoints and DNA replication
Human cells maintain genetic integrity by detecting
DNA damage and activating cell cycle checkpoints and
DNA repair pathways [43]. The G1/S, intra-S, and the
G2/M checkpoints, are mediated by ATM/ATR and
checkpoint kinases 2 and 1 (CHK2)/(CHK1), respectively











































Figure 1 Mechanism(s) of hypoxia-driven genetic instability. Hypoxia/anoxia signalling and subsequent adaptive biology is mediated by
HIF1α transcription factors and altered protein through the unfolded protein response (UPR). These transcriptional and translational responses
inhibit DNA repair by homologous recombination, non-homologous end-joining, and mismatch repair. The proteins downregulated by hypoxia
are underlined. As a result, increased unrepaired double-strand breaks, replication errors and decreased centrosome function can accelerate
genetic instability and lead to an aggressive, mutator phenotype.
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and G2/M) to prevent cell cycle progression or to initi-
ate programmed cell death [44,45]. Cycles of hypoxia
followed by reoxygenation in tumors cyclically activates
many DNA damage response (DDR) proteins. Further-
more, ATM, DNA-PKcs, H2AX, p53, CHK1, CHK2,
53BP1 and NBS1 are phosphorylated under conditions
of severe hypoxia (<0.02%) in the absence of exogenousDNA damage [18,41,46-51]. Anoxia therefore leads to cell
cycle arrests at G1 and intra-S in the absence of DNA
damage, and in turn, reoxygenation causes CHK2-
mediated G2 arrest [12,19,21,22,38,52]. When an arrested
hypoxic cell becomes reoxygenated, it may either resume
proliferation or undergo an irreversible loss of DNA repli-
cation ability and undergo cell death [38,53-55]. The
length of the hypoxic stress may determine the ultimate
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pend on the level of hypoxia. For example, oxygen levels
such as 0.2% do not activate ATM or ATR and cell cycle
checkpoint signaling [56]. Propagation of such a tumor
cell with potentially altered DNA damage signaling and
reoxygenation-induced DNA damage, can contribute to
genetic instability and malignant progression [38].
HIF1α can also bind directly to minichromosome
maintenance (MCM) proteins that are responsible for
unwinding the DNA during replication [57]. Direct
interaction between HIF1α and MCM7 results in in-
creased prolyl hydroxylation-dependent HIF1α degrad-
ation, and an interaction with MCM3 results in HIF1α
transactivation domain function inhibition [58]. HIF1α
can block replication origin firing and DNA replication
by binding to Cdc6, which is involved in recruiting
MCM helicases to replication origins. HIF1α-Cdc6 inter-
action leads to enhanced MCM helicase loading and de-
creased recruitment of Cdc7 to replication origins,
resulting inhibition of replication origin firing and over-
all DNA replication [57].
Hypoxia causes microsatellite and chromosomal
instability
Studies have also documented an increased rate of spon-
taneous DNA mutations in cells exposed to hypoxia using
reporter assays. This further supports the view of tumor
microenvironment as a driving force of genomic instability
(see Table 1) [59-62]. The concept of genetic instability
covers a wide variety of genetic alterations from point mu-
tations to chromosomal number. These changes are di-
vided into two types: microsatellite instability (MSI) and
chromosomal instability [63]. MSI is typically found in
colorectal cancers and is caused by defective DNA mis-
match repair (MMR) [64]. As hypoxia downregulates
MMR, a model of tumor microenvironment-driven MSI
has been proposed. This suggestion is supported by stud-
ies both in vitro and in vivo of colorectal cancer models
[65-67]. High level of HIF1α associates with MSI in hu-
man colorectal carcinoma [68,69]. Further investigation in
clinical settings will show whether the mechanistic labora-
tory findings of HIF-MMR-MSI can be generalized to
other cancers in addition to colon carcinomas.
DNA double-strand break (DSB) repair is crucial for
chromosomal integrity. Unrepaired DSBs can lead to
formation of deletions, insertions, translocations and
amplifications [83,84]. For example, cells deficient for
BRCA1/2 develop spontaneous gross chromosomal aber-
rations [85-89]. Hypoxia is known to both inhibit DSB
repair and to promote chromosomal instability in mul-
tiple ways [71,73,90]. Fragile sites are specific chromo-
somal regions prone to chromosomal breakage and
rearrangements during replication stress and are induced
under hypoxia [73,91]. This could be, in part, explainedby hypoxia-mediated downregulation of DSB repair
genes, as RNAi inhibition of DSB repair results in fragile
site activation [92]. Additionally, ATM and ATR kinases
maintain fragile site stability, and DSB biomarkers γ-
H2AX and DNA-PKcsThr2609 foci localize at fragile sites
[92,93]. An unrepaired DSB can also lead to DNA ampli-
fication, which has been observed in hypoxic cells
[70,71,75,79,94]. Additionally, the frequency of sister
chromatid exchange (SCE), which is in part controlled
by homologous recombination (HR) repair, may be in-
creased in hypoxic primary human lymphocytes [81,95].
Human fibroblasts subjected to continual hypoxic condi-
tions following exogenous DNA damage maintained in-
creased chromosomal aberrations such as chromosome
breaks, chromatid breaks, ring chromosomes, telomeric
fusions, reciprocal translocations and double minutes
[82]. Finally, hypoxia may also induce global deacetyla-
tion and methylation of histones, phosphorylation of
H2AX and altered condensation states within the chro-
matin [90].
In order to prevent mitotic errors leading to genetic
instability, the cell must properly align chromosomes
during mitosis. The mitotic spindle is generated by the
activity of centrosomes, which are composed of centri-
oles and pericentriolar material [96]. Defects in centro-
somes and spindle formation lead to aneuploidy during
the process of carcinogenesis and tumor progression
[97,98]. Recently, a study has shown that hypoxia can
modify centrosome function by altering the activity
of prolyl-4-hydroxylases (PHDs) towards the protein
Cep192 (a critical component of the centrosome) [99].
This allows for mediating signaling between oxygen
tension and cell cycle control. Further studies are required
to investigate whether these and other genes that are in-
volved in mitosis and centrosome organization are altered
in cancer cells within hypoxic sub-regions of solid tumors.
Altogether, these studies support the concept that hyp-
oxia can modify fragile sites, the repair of DNA damage,
chromatin biology, and possibly mitosis in promoting
genetic instability during tumor progression.
Hypoxia-mediated inhibition of DNA repair
The understanding of hypoxia in the context of signal-
ing and DNA repair is increasing based on data using
isogenic models that vary in specific DNA repair path-
ways. Below, we discuss the mechanisms of DNA repair
downregulation in hypoxic cells in a pathway-specific
manner (Figure 1).
DNA double-strand break repair
Ionizing radiation (IR) or radiomimetic drugs create DSBs,
which are mainly repaired by HR or non-homologous
end-joining (NHEJ) pathways in a cell cycle-dependent
manner [100]. The proteins RAD51, BRCA1/2 and the
Table 1 Evidence linking hypoxia to tumor cell genetic instability
Author % Oxygen Cell system Assays Key findings
Rice et al. [70] 0% AA8 (CHO) Flow cytometry, gene
copy analyses
- Anoxia induces S-phase
overreplication and increases
the frequency of dihydrofolate
reductase gene amplification
Young et al. [71] 0% (<10 ppm) KHT-C2-LP1 (M-fibrosarcoma), Metastasis assay, flow
cytometry
- Anoxia induces DNA
overreplication and increases
metastatic potentialB16F10-A1 (M-melanoma)
Reynolds et al. [61] 0% (<10 ppm) LN12 (M-fibroblasts) Chromosome based λ
shuttle vector, PCR, DNA
sequence analysis
- Anoxia induces 3–4 fold increase
in supF tRNA suppressor gene
mutation (transversions and
deletions) frequency
Rofstad et al. [72] 0% (<10 ppm and <100 ppm) BEX-c (H-melanoma), Flow cytometry, Giemsa - Anoxia followed by reoxygenation
induces diplochromosomes and
tetraploidizationSAX-c (H-melanoma)




- Severe hypoxia induces fragile
sites and generates homogeneously
stained regions (HSRs)
Yuan et al. [74] 0% (<10 ppm) 3340 (M-fibroblast) Host cell reactivation
(HCR) assay, UV
mutagenesis assay
- Anoxia induces 2-fold increase in
supFG1 mutation frequency





- Severe hypoxia activates fragile
sites and generates double minutes
and dicentric chromosomes





- Anoxia induces 2-fold increase in
supFG1, cII and lacZ mutation
frequency
Banath et al. [77] i.p. pimonidazole V79-VE (Chinese hamster
fibroblasts),
Flow cytometry, γ-H2AX
foci, HPRT mutation assay,
alkaline comet assay
- Hypoxia (cells distant to the blood
vessels) followed by reoxygenation
does not alter mutation frequency
at HPRT locus, DNA strand break
rejoining or resolution of γ-H2AX




Koshiji et al. [78] 1% HCT116 (H-colon carcinoma), β-galactosidase mutation
assay, microsatellite analysis
- Hypoxia increases the frequency
of microsatellite mutations
HEC59 (H-endometrial carcinoma)
Papp-Szabo et al. [59] 0% ME (R-mammary epithelial cells), cII mutagenicity assay - Anoxia increases the mutation




Fischer et al. [79] 0% TX3868 (H-glioblastoma) Fluorescence in situ
hybridization (FISH)
- Anoxia induces double minutes,
fragile sites and anaphase-bridges



















Table 1 Evidence linking hypoxia to tumor cell genetic instability (Continued)









- Hypoxia increases mutation
frequency of the β-galactosidase
reporter gene and causes
microsatellite instability
Keysar et al. [60] <0.1% AL(N) (CHO) Complement cytotoxic
assay, flow cytometry
mutation assay
- Anoxia results in a significant
induction of mutations especially
large deletions in CD59 gene





- Hypoxia increases SCE but does
not alter microsatellite instability






- Anoxia blocks DNA replication at
the initiation and elongation stages
and compromises DNA replication
restart - Acute anoxia following
reoxygenation (cycling hypoxia)
does not affect DNA replication
restart
Kumareswaran et al.* [82] 0.2% GM05757 (H-fibroblasts) Giemsa, Multicolor
fluorescence in situ
hybridization (M-FISH)
- Hypoxia increases the frequency of





CHO – Chinese hamster ovary cells; M – mouse; H – human; R – rat.
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HR during S and G2 phases of the cell cycle. Proteins such
as KU70/80, DNA-PKcs and DNA-ligase IV function in
NHEJ across all phases of the cell cycle [100].
The majority of HR proteins are repressed by chronic
hypoxia [101]. This can occur through decreased tran-
scription, translation, miRNA modulation and epigenetic
silencing. The first mechanistic model suggests that HIF1α
competes with and opposes MYC activity in hypoxic cells,
inhibiting Brca1 and Nbs1 transcription [35,102-104]. An-
other model proposes that HR gene expression, including
Rad51 and Brca1, is repressed by the E2F-4/p130 complex
independent of HIF [105-107]. The HIF-independent
mechanism is supported by observations of downregulated
RAD51 in isogenic HIF1α−/− mouse embryo fibroblasts
(MEFs) under hypoxia, albeit by reduced efficiency [108].
Studies from our laboratory support a third model involv-
ing selective inhibition of protein synthesis. Hypoxia alters
protein synthesis by pathways that modulate gene expres-
sion in both transcript-specific and a global manner; via
unfolded protein response (UPR) and mammalian target
of rapamycin (mTOR) signaling [109]. Our findings indi-
cate that in chronically hypoxic proliferating cells, RAD51
and BRCA2 are downregulated due to selective inhibition
of mRNA translation [56]. Yet another layer to hypoxia-
regulated HR expression involves altered chromatin modi-
fication and Brca1 promoter silencing in severe hypoxia
[110]. Finally, miRNA may play a role in HR suppression
and can affect Rad52 gene expression [111].
The impact of hypoxia and DNA repair on malignant
progression is demonstrated in studies indicating that
repressed HR is linked with cancer initiating cell forma-
tion [112]. Breast tumor-initiating cells overexpress poly-
comb protein EZH2, which is further induced by HIF1α
under hypoxia [112,113]. EZH2 inhibits Rad51 transcrip-
tion in hypoxic CD44+CD24-/low cells, which is associ-
ated with increased genomic abnormality [112]. This
EZH2-RAD51 signaling (via RAF1 amplification) pro-
motes mammosphere formation and malignant progres-
sion [112].
The function of NHEJ in hypoxia-driven genetic in-
stability and radiation response is more controversial.
Inhibited expression of DNA-PKcs, Ku70, Ku80 and DNA-
ligase IV has been observed under hypoxia [101,114].
NHEJ factors are downregulated in hypoxic wild-type
MEFs and in normoxic HIF1α−/− MEFs [115]. In cervical
tumors, KU70/KU80 expression correlates with oxygen
pressure and is inhibited with increasing distance to blood
vessels [116]. We observed an increase in residual DSBs in
G0/G1 synchronized human fibrobalsts under hypoxic
conditions following exogenous DNA damage (Figures 2
and 3) [82]. On the other hand, induction of Ku70 may
occur under hypoxia in some cell lines [114]. KU70 could
indeed contribute to hypoxic tumor cell resistance toradiation, as expression of a dominant negative form of
KU70 sensitizes hypoxic glioma and colorectal cells to ra-
diation [117]. Other reports have proposed redundancy or
increased NHEJ under hypoxia [118-120]. An outstanding
question in the field is whether the MRN complex, ATM
and DNA-PKcs kinases differentially sense DSBs under
oxia vs hypoxia (Figure 1). Varying model systems and
tumor microenvironment conditions might explain the
differing observations, and further investigation will clarify
the role of hypoxia in NHEJ control.
Mismatch repair
MMR repairs DNA base substitutions and misalign-
ments, which occur during DNA replication [122].
Mammalian MMR uses proteins such as MutSα
(MSH2 +MSH6), MutSβ (MSH2 +MSH3), and MutLα
(MLH1 + PMS2) [122].
The involvement of MMR in the hypoxic response is
fairly well characterized. The hypoxia-driven genetic in-
stability in colorectal cancers is consistent with inhibited
Mlh1 transcription in low oxygen [76]. Mechanistically,
MMR inhibition under hypoxia involves at least MYC
and DEC transcription factors. Interplay of HIF1α and
MYC has been suggested to regulate MMR expression;
MYC-dependent regulation of MSH2 and MSH6 in
oxic cells may be replaced by HIF1α under hypoxia
[35,78,104]. In addition, knockdown of HIF1α reverses
hypoxia-driven inhibition of MMR expression [78,123].
Repression of MMR gene expression by decreased MYC
and increased MAX, MAD and MNT association on
Mlh1 and Msh2 promoters have been observed in hyp-
oxic cells [107]. MYC, MAD and MNT (as part of the
“max network” containing basic helix-loop-helix zipper
(bHLHZ) motifs) form heterodimers with MAX result-
ing in sequence-specific DNA binding [124]. These
DNA-bound heterodimers can then alter chromatin
structure to modulate transcription [124]. Additionally,
hypoxia-induced transcription repressors DEC1 and
DEC2 contribute to Mlh1 inhibition [125]. Hypoxic
MMR regulation is also influenced by the state of chro-
matin acetylation [66,76,80,125].
Nucleotide excision repair and Fanconi anemia pathway
Chemicals covalently bound to DNA forming bulky ad-
ducts, as well as chemical-caused DNA crosslinks and
UV-induced DNA lesions, are repaired by nucleotide
excision repair (NER). NER in mammals uses two path-
ways: global genome repair (GGR) and transcription-
coupled repair (TCR) [126]. GGR involves multiple
sequential steps including sensing of the lesion (XPC-
HR23B-Centrin 2 complex), opening of a denaturation
bubble (TFIIH, XPA-RPA complex), incision of damaged
strand (XPG, XPF-ERCC1 complex), displacement of









































Figure 2 Decreased repair of DNA double strand breaks (DNA-DSBs) under continual hypoxia. A, Despite a decrease in the initial number
of induced and sensed DSBs measured by γ-H2AX foci at 30 minutes following 2 Gy, hypoxic (0.2% O2) G0/G1 synchronized human fibroblasts
have an increased number of residual γ-H2AX foci at 24 hours. The asterisk represents a significant difference (*P < 0.05) between oxic control
(solid) and hypoxic treatment (dashed). Plot is adapted from data published in Kumareswaran et al. [82]. B, Two dimensional (top panels) and
three dimensional (bottom panel) confocal images of G0/G1 fibroblasts with increased number of residual γ-H2AX foci under continual hypoxia
at 24 hours following 2 Gy of irradiation. Scale bar = 10 μm.
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the other hand, TCR requires CSA, CSB and XAB2 to
sense the lesion and proceeds to GGR for the next se-
quential steps [126]. Both decreased and increased abil-
ity of cells to repair UV-damaged DNA in conditions of
hypoxia and low pH have been reported [74,120]. Indica-
tion for NER in the hypoxic response comes from find-
ings of XPC and XPD as direct HIF1α targets, and
inhibition of HIF1α perturbs the removal of UVB-
induced 6–4 photoproducts (6-4PPs) and cyclobutane
pyrimidine dimers (CPDs) [127]. Also, HIF1α associateswith the gene promoter of CSB/ERCC6, which functions
in recruiting NER repair proteins to the damaged DNA,
and is induced by hypoxia. CSB mutant cells fail to acti-
vate HIF-dependent hypoxic response [128]. Finally,
RAD23B protein is repressed under hypoxia and by
miRNA-373 [111]. Further investigation is needed to es-
tablish the role of hypoxia in NER.
Fanconi anemia (FA) is a hereditary disorder with
predisposition to cancer [129]. The FA pathway includes
14 FANC genes, which function in ubiquitination-









































































Figure 3 (See legend on next page.)
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Figure 3 Hypoxia induces chromosomal aberrations following exogenous damage. A, Chromatin bridges or anaphase bridges in fibroblasts
maintained under continual hypoxic (0.2% O2) conditions following 2 Gy of irradiation. These bridges can break into fragments and give rise to
micronuclei [121]. The type, the number, and the fate of chromosome bridges under hypoxia is not known and requires further investigation.
Representative DAPI stained and M-FISH images of fibroblasts are shown. Scale bar = 10 μm. B, M-FISH karyotype of fibroblasts maintained under
oxic (21% O2) conditions following 2 Gy of irradiation or hypoxic (0.2% O2) conditions following 2 Gy of irradiation. Shown are reciprocal
translocation between chromosomes 2 and 17, loss of chromosome 20 and two extra copies of chromosome Y in hypoxic cells following 2 Gy of
irradiation. C, Percentages of chromosomal aberrations in oxic and hypoxic fibroblasts as measured by Giemsa staining analysis. NIR = non-
irradiated; white columns = oxia (21% O2); black columns = hypoxia (0.2% O2). D, Percentages of chromosomal aberrations in oxic and hypoxic
fibroblasts as measured by M-FISH analysis. NIR = non-irradiated; white columns = oxia (21% O2); black columns = hypoxia (0.2% O2). Plots are
based on quantitative assessment of data published in Kumareswaran et al. [82].
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(mitomycin C) MMC or cisplatin [129]. Little is known
regarding the role of FANC in the hypoxic response.
However, FANCC and FANCD2 cells exhibit increased
IR sensitivity under hypoxia compared to wild-type cells
[118,130]. UBE2T is an E2 conjugating enzyme that
operates in the FA pathway to mono-ubiquitinate
FANCD2 and FANCI. UBE2T expression is inhibited
under hypoxia by a mechanism involving decreased pro-
moter activity, independent of HIF1α, HIF1β or HIF2α.
Consistent with the FA phenotype, both anoxic and
UBE2T knockdown cells are hypersensitive to MMC-
induced DNA crosslinks [131].
Therapeutic targeting of hypoxic tumor cells
The success of anti-cancer therapies is currently chal-
lenged by increased local and systemic resistance of
tumor cells residing in the hypoxic microenvironment.
However, the hypoxic phenotype can also provide an
opportunity to specifically target cells in the tumor
microenvironment and improve the therapeutic index
(e.g. kill more cancer cells than normal cells) (see
Figure 4). The development of therapeutic agents that
are selectively activated upon exposure to low oxygen is
of great interest [32]. For example, tirapazamine and
apaziquone, both bioreductive prodrugs that induce
DNA damage, have been tested in Phase III clinical trials
[32]. A newer compound, TH-302, is a 2-nitroimidazole
triggered hypoxia-activated prodrug of the cytotoxin
bromo-isophosphoramide mustard (Br-IPM), which causes
DNA damage under hypoxic/anoxic conditions [132].
The antitumor activity of TH-302 has been shown to
be dose-dependent and decreased the hypoxic fraction
in xenografts of varying histology. TH-302 also induces
DNA damage (as measured by γ-H2AX) in hypoxic
regions in vivo and can further kill cells through a
time-dependent “bystander effect”. This compound is
currently in Phase II-III clinical trials in combination
with chemotherapy.
Translational control is an important contributor to
the hypoxic adaptation and gene expression alongside
with HIF-dependent pathways [109]. Therefore, targetingmTOR and UPR could provide another opportunity to en-
hance selective tumor cell kill [32,133,134]. Clinically rele-
vant agents that influence mTOR or UPR signaling
include for example imatinib, nelfinavir and sunitinib,
which can improve tumor oxygenation and inhibit angio-
genesis [109,135].
Synthetic lethality is a phenomenon that arises when
mutations in two or more genes result in cell death,
while a cell with a mutation in either gene alone is viable
[136]. Over the recent years, this has started to attract
attention as a way to attack the Achilles’ heel of a cancer
cell. For example, inhibition of poly(ADP-ribose) poly-
merase (PARP), which normally functions in single-
strand break (SSB) and base-excision repair (BER), is
synthetically lethal with BRCA-deficient tumors [137]. In
addition to targeting cancerous mutations, synthetic le-
thality based on tumor microenvironment has emerged,
where the extrinsic differences of tumor cells are used to
widen the therapeutic index [136]. In this “contextual”
synthetic lethality, the hypoxic phenotype with defective
DNA repair can be exploited, together with inhibiting a
backup DNA repair pathway, to specifically kill hypoxic
cells. Therapies would therefore preferentially kill tumor
cells with reduced DNA repair capacity, and spare nor-
mal tissue with physiological oxygenation state and func-
tional DNA repair. Indeed, hypoxic HR-defective cells
are sensitive to PARP inhibition [108,138]. PARP inhib-
ition induces DNA damage in proliferating cells and kills
hypoxic cells specifically in S phase [108]. Synthetic
lethality in the HR pathway has also been documented
between RAD52 and BRCA2, as well as between splicing
factor proline and glutamate-rich (SFPQ)/PSF and RAD51D
[139,140]. Additionally, PTEN null astrocytes were
found to be sensitive to PARP inhibition due to lower
expression of Rad51B-D [141]. However, recent data
from our laboratory failed to observe a correlation be-
tween PTEN status and RAD51 function [142].
In MMR, inhibition of POLB in MSH2-deficient; and
inhibition of POLG in MLH1-deficient cells, produces a
synthetic lethal phenotype [143]. An siRNA screen iden-
tified inhibited PTEN-induced putative kinase 1 (PINK1)
















(inhibit HIF1 , mTOR)
Direct Hypoxic Cell Killing 
(TH-302,Tirapazamine)
Use of Contextual Synthetic Lethality
(Decreased transcription, translation, function of DNA repair)
Figure 4 Targeting of hypoxic cells in cancer treatment. Hypoxic cells can be quantitated in situ by staining for antibodies that measure
uptake of nitroimidazole compounds (which are reduced in hypoxic environments and bind to SH-containing molecules such as glutathione and
proteins); one such compound is pimonidazole (PIMO). These studies, in addition to direct measurements of pO2, have linked the proportion of
hypoxic cells to aggressive tumor cell variants that are resistant to radiotherapy, chemotherapy and have an increased propensity for metastases.
Direct targeting with agents that create DNA damage solely under hypoxic conditions (e.g. TH-302) or inhibit selective pathways activated in
hypoxic cells (e.g. HIF1α and mTOR signaling) may improve the overall cell kill within a tumor volume when used alone or with radiotherapy or
chemotherapy. Hypoxia may also lead to differential transcription or translation of DNA repair or replication genes which can reduce the function
of the repair pathway. These repair-deficient hypoxic cells can be killed by agents that target remaining back-up pathways leading to cell death.
Given the repair defect is secondary to the effects of hypoxia as opposed to a primary somatic or germline defect, this type of cell kill is denoted,
“contextual synthetic lethality” given it is contextual on the local tumor microenvironment and varies depending on the metabolic state of the
cancer cell.
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regulated under hypoxia, determining whether these
synthetic lethal interactions could be exploited to target
hypoxic tumor cells, would be of great interest. Future
investigations will show if these observations could have
an impact on radiation- and clinical oncology.
Conclusions
A number of molecular mechanisms have been proposed
to explain hypoxic inhibition of HR and MMR-mediated
DNA repair based on biochemical and cell biologyendpoints. Molecular pathways may play differing roles
depending on tissue type, microenvironment conditions
and proliferation status; or alternatively, each might have
a relative contribution for a global DNA repair-deficient
phenotype. Dissecting these pathways could help design-
ing anti-cancer treatments that inhibit DNA repair and
sensitize tumor cells to radio- and chemotherapies. Also,
a better understanding of therapies targeting the prolif-
erating hypoxic cell subpopulations could increase se-
lective killing of resistant tumor cells. Clinical trials
using these approaches will require careful assessment
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techniques in order to incorporate hypoxia assessment
as a part of a standard of care. This approach will serve
well to be one step closer to individualized cancer medi-
cine and improved patient outcome.
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